Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Rheumatology|January 17, 2016
Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic ArthritisPhilip J Mease, Mark C Genovese, Alex Mutebi, et al.
The American Journal of Clinical Nutrition|February 8, 2007
Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspectiveSteven B Heymsfield, Joyce B Harp, Marc L Reitman, et al.
Rheumatology (Oxford, England)|November 19, 2016
Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseasesAjay Nirula, Jon Nilsen, Paul Klekotka, et al.
Health and Quality of Life Outcomes|June 10, 2009
One-year health-related quality of life outcomes in weight loss trial participants: comparison of three measuresRonette L Kolotkin, Josephine M Norquist, Ross D Crosby, et al.
The New England Journal of Medicine|June 13, 2017
Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesBruce Neal, Vlado Perkovic, Kenneth W Mahaffey, et al.
The AAPS Journal|June 29, 2010
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonistXiujiang Susie Li, Jace Nielsen, Brenda Cirincione, et al.
Arthritis Care & Research|July 25, 2015
Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic ArthritisHilary D Wilson, Alex Mutebi, Dennis A Revicki, et al.
The New England Journal of Medicine|June 12, 2014
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritisPhilip J Mease, Mark C Genovese, Maria W Greenwald, et al.
The Lancet. Diabetes & Endocrinology|June 26, 2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsVlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, et al.
Circulation|November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.
Pageof 4